CN119306830B - Anti-cortisol antibodies, reagents and kits for detecting cortisol - Google Patents

Anti-cortisol antibodies, reagents and kits for detecting cortisol Download PDF

Info

Publication number
CN119306830B
CN119306830B CN202310851433.7A CN202310851433A CN119306830B CN 119306830 B CN119306830 B CN 119306830B CN 202310851433 A CN202310851433 A CN 202310851433A CN 119306830 B CN119306830 B CN 119306830B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310851433.7A
Other languages
Chinese (zh)
Other versions
CN119306830A (en
Inventor
钟冬梅
孟媛
梁碧
王林聪
唐丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Pengzhi Biotechnology Co Ltd
Original Assignee
Dongguan Pengzhi Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Pengzhi Biotechnology Co Ltd filed Critical Dongguan Pengzhi Biotechnology Co Ltd
Priority to CN202310851433.7A priority Critical patent/CN119306830B/en
Publication of CN119306830A publication Critical patent/CN119306830A/en
Application granted granted Critical
Publication of CN119306830B publication Critical patent/CN119306830B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses an anti-cortisol antibody or a reagent and a kit for detecting cortisol, and relates to the field of antibodies. The anti-cortisol antibodies disclosed herein comprise a heavy chain complementarity determining region and a light chain complementarity determining region, and provide an important source of raw materials for the detection of cortisol, and have good affinity or activity.

Description

Anti-cortisol antibodies, reagents and kits for detecting cortisol
Technical Field
The invention relates to the technical field of antibodies, in particular to an anti-cortisol antibody, a reagent for detecting cortisol and a kit.
Background
Cortisol (Cortisol), also known as hydrocortisone, hydrocortisone or compound F. The human cortisol secretion is regulated by hypothalamic-pituitary-adrenal axis, and pituitary gland secretes adrenocorticotropic hormone (ACTH) when the human brain senses stress, promoting proliferation of adrenocortical tissue and production and secretion of corticoids. The human body secretes cortisol regularly, the cortisol level in one day rises sharply within 30 minutes after getting up in the morning, reaches the highest value about 30-45 minutes after getting up, and then gradually falls within one day until reaching the lowest value before sleeping.
Under normal conditions, cortisol can reduce sodium loss, temporarily improve memory, and help remove toxins in the liver. Cortisol helps to maintain blood pressure stable and control excessive inflammation under stress. However, excessive cortisol secretion has a negative effect on the human body. Especially when people repeatedly bear weight, life rhythm is tension, long-term diet and long-term sleep are insufficient, the cortisol is excessively secreted for a long time. At this time, cortisol may cause an increase in blood sugar, an increase in appetite, an increase in body weight, a decrease in sexual desire, and extreme fatigue. In addition, abnormal secretion of cortisol can also cause symptoms in humans. Cushing's syndrome is a condition resulting from typical hypersecretion of cortisol, characterized by rapid weight gain, hyperhidrosis, susceptibility to bruising, and psychological disorders. Furthermore, generalized anxiety disorder (Generalized anxiety disorder, GAD) is also closely related to abnormal cortisol secretion in humans. The lifetime prevalence of the disease in adults is estimated to be 4.1% -6.6% with female patients being 2 times that of men. It not only seriously affects the life quality, psychological health and social function of the patient, but also can co-treat other diseases at the same time, and increases suicide risk. The detection of cortisol content is helpful for analysis and judgment of human health status, including diagnosis of adrenal function status, indirect observation of pituitary function status, cushing's syndrome, cardiovascular disease, stress and mental disease. Therefore, the cortisol in the human body can be effectively detected in time, and the method has important significance for knowing the current own physical condition.
Cortisol is usually determined by an immunological method or an LC-MS method. LC-MS methods, although accurate and sensitive, require expensive equipment and are therefore difficult to popularize in the laboratory. The immune method has the characteristics of high sensitivity, low detection cost, high feasibility and the like, and is suitable for wide popularization and application. Immunological detection methods all require antibodies to cortisol. Thus, there is a strong need in the art for antibodies that bind to cortisol efficiently and detect it.
Disclosure of Invention
The application provides an antibody or an antigen binding fragment thereof, which provides an important raw material source for detecting cortisol and has good activity or affinity.
In order to achieve the above object, according to one aspect of the present invention, there is provided an antibody or an antigen-binding fragment thereof comprising three complementarity determining regions having a heavy chain variable region represented by amino acid sequence SEQ ID NO. 17 and three complementarity determining regions having a light chain variable region of any one of amino acid sequences SEQ ID NO. 18, 19, 20.
In order to achieve the above object, according to a second aspect of the present invention, there is provided an antibody or an antigen-binding fragment thereof comprising the following complementarity determining regions:
HCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO. 1;
HCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID No. 2;
HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID No. 3;
LCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 4;
LCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 5;
LCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 6.
In order to achieve the above object, according to a third aspect of the present invention, there is provided an antibody or antigen-binding fragment thereof comprising a heavy chain variable region having an amino acid sequence shown in SEQ ID NO. 17 and/or a light chain variable region having an amino acid sequence shown in any one of SEQ ID NO. 18, 19 and 20.
In order to achieve the above object, according to a fourth aspect of the present invention, there is provided an antibody or antigen-binding fragment thereof, comprising a heavy chain having an amino acid sequence as shown in any one of SEQ ID NOS: 21 and/or a light chain having an amino acid sequence as shown in any one of SEQ ID NOS: 22, 23, 24.
In order to achieve the above object, according to a fifth aspect of the present invention, there is provided an antibody conjugate comprising the above antibody or antigen-binding fragment thereof.
In order to achieve the above object, according to a sixth aspect of the present invention, there is provided a reagent or kit comprising the above antibody or antigen-binding fragment thereof or the above antibody conjugate.
In order to achieve the above object, according to a seventh aspect of the present invention there is provided a method of detecting cortisol comprising a) contacting an antibody or antigen binding fragment thereof, antibody conjugate, or reagent or kit as described above with cortisol in a sample to be detected under conditions sufficient for an antibody/antigen binding reaction to occur to form an immune complex, and b) detecting the presence of said immune complex, the presence of said complex being indicative of the presence of said antigen in said test sample.
In order to achieve the above object, according to an eighth aspect of the present invention, there is provided a nucleic acid encoding the above antibody or antigen-binding fragment thereof.
In order to achieve the above object, according to a ninth aspect of the present invention, there is provided a vector comprising the nucleic acid described above.
In order to achieve the above object, according to a tenth aspect of the present invention, there is provided a cell comprising the above nucleic acid, vector or antibody or antigen-binding fragment thereof expressed as described above.
In order to achieve the above object, according to an eleventh aspect of the present invention, there is provided a method for producing the above antibody or antigen-binding fragment thereof, the method comprising culturing the above cell.
In order to achieve the above object, according to a twelfth aspect of the present invention, there is provided the use of an antibody or antigen binding fragment, antibody conjugate, reagent or kit as described above for the detection or preparation of a product for detecting cortisol.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the results of reducing SDS-PAGE of Anti-CORT 20D9 Rmb1 to Rmb.
Detailed Description
In a first aspect, the invention provides an antibody or antigen-binding fragment thereof comprising three complementarity determining regions having the heavy chain variable region set forth in amino acid sequence SEQ ID NO. 17 and three complementarity determining regions having any one of the light chain variable regions of amino acid sequences SEQ ID NO. 18, 19, 20.
The HCDR1, HCDR2 and HCDR3 are amino acid sequences identical to the HCDR1, HCDR2 and HCDR3 of the same heavy chain variable region defined in the antibody or antigen-binding fragment thereof according to the first aspect, and the LCDR1, LCDR2 and LCDR3 are amino acid sequences identical to the LCDR1, LCDR2 and LCDR3 of the same light chain variable region defined in the antibody or antigen-binding fragment thereof according to the first aspect.
For example, the HCDR1, HCDR2 and HCDR3 are amino acid sequences identical to HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO. 17, and the LCDR1, LCDR2 and LCDR3 are amino acid sequences identical to LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO. 18.
In the present invention, the term "antibody" is used in the broadest sense and may include full length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies so long as they exhibit the desired biological activity.
In the present invention, the terms "complementarity determining regions", "CDRs" or "CDRs" refer to the highly variable regions of the heavy and light chains of immunoglobulins, and refer to regions comprising one or more or even all of the major amino acid residues responsible for the binding of an antibody or antigen-binding fragment to the antigen or epitope recognized by it. In a specific embodiment of the invention, CDRs refer to the highly variable regions of the heavy and light chains of the antibody.
In the present invention, the heavy chain complementarity determining region is represented by HCDR and includes HCDR1, HCDR2 and HCDR3, and the light chain complementarity determining region is represented by LCDR and includes LCDR1, LCDR2 and LCDR3.
CDR definition methods are well known in the art and include Kabat definition, chothia definition, IMGT definition, contact definition and AbM definition. As used herein, "Kabat definition" refers to the definition system described by Kabat et al, U.S. Dept. Of HEALTH AND Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" see Chothia et al, J Mol Biol 196:901-917 (1987). Still other CDR definition methods may not strictly follow one of the above schemes, but still overlap at least a portion of the Kabat-defined CDR regions, although they may be shortened or lengthened depending on the predicted or experimental outcome of a particular residue or group of residues. Exemplary defined CDRs are listed in table 1 below, with slightly different definitions in the different documents. Given the variable region amino acid sequence of an antibody, one of skill in the art can routinely determine which residues comprise a particular CDR. It should be noted that CDRs defined by other methods not limited to table 1 are also within the scope of the disclosure.
TABLE 1 CDR definition 1
1 The numbering of all CDR definitions in Table 1 is according to the Kabat numbering system (see below), with the amino acid numbers on the heavy chain being indicated by "H+ numbers" and the amino acid numbers on the light chain being indicated by "L+ numbers". The Kabat numbering system can be specifically mapped to any variable region sequence by one of ordinary skill in the art without relying on any experimental data outside of the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al, U.S. Dept. Of HEALTH AND HumanServices, "Sequence of Proteins of Immunological Interest" (1983).
2 The "AbM" as used in table 1 has a lower case "b" referring to CDRs defined by the "AbM" antibody modeling software of Oxford Molecular.
3 CDR-H1 ends at position 35 if both H35A and H35B are absent, CDR-H1 ends at position 35A if only H35A is present, and CDR-H1 ends at position 35B if both H35A and H35B are present.
4 CDR-H1 ends at bit 32 if both H35A and H35B are absent, at bit 33 if only H35A is present, and at bit 34 if both H35A and H35B are present.
5 CDR-H1 ends at position 33 if both H35A and H35B are absent, CDR-H1 ends at position 34 if only H35A is present, and CDR-H1 ends at position 35 if both H35A and H35B are present.
According to an embodiment of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one system or combination of systems Kabat, chothia, IMGT, abM or contacts.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Kabat system.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Chothia system.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by an IMGT system.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by an AbM system.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Contact system.
In some alternative embodiments of the invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by Kabat, chothia, IMGT, abM or Contact system combinations.
In some alternative embodiments of the present invention, the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 defined by the Kabat, chothia, abM or IMGT system correspond to the following Kabat numbering positions:
CDR Kabat AbM IMGT Chothia
HCDR1 H31~H35 H26~H35 H26~H33 H26~H32
HCDR2 H50~H65 H50~H58 H51~H57 H52~H56
HCDR3 H95~H102 H95~H102 H93~H102 H95~H102
LCDR1 L24~L34 L24~L34 L27~L32 L24~L34
LCDR2 L50~L56 L50~L56 L50~L51 L50~L56
LCDR3 L89~L97 L89~L97 L89~L97 L89~L97
in a second aspect, the invention provides an antibody or antigen-binding fragment thereof comprising the complementarity determining regions:
HCDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO. 1;
HCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID No. 2;
HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID No. 3;
LCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 4;
LCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 5;
LCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO. 6.
In alternative embodiments, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Kabat system.
In the present invention, a "framework region" or "FR" region includes a heavy chain framework region and a light chain framework region, which refers to regions of an antibody heavy chain variable region and a light chain variable region other than CDRs, wherein the heavy chain framework region can be further subdivided into contiguous regions separated by CDRs, including HFR1, HFR2, HFR3, and HFR4 framework regions, and the light chain framework region can be further subdivided into contiguous regions separated by CDRs, including LFR1, LFR2, LFR3, and LFR4 framework regions.
In the present invention, the heavy chain variable region is obtained by ligating the CDRs numbered from HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4 with the FRs in a combinatorial arrangement, and the light chain variable region is obtained by ligating the CDRs numbered from LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4 with the FRs in a combinatorial arrangement.
In some optional embodiments of the invention, the antibody or antigen binding fragment thereof of the first or second aspect further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR 4;
The HFR1 comprises/has an amino acid sequence as shown in SEQ ID NO 7 or having at least 80% identity thereto;
The HFR2 comprises/has an amino acid sequence as shown in SEQ ID NO 8 or having at least 80% identity thereto;
The HFR3 comprises/has as SEQ ID NO 9 or an amino acid sequence having at least 80% identity thereto;
The HFR4 comprises/has an amino acid sequence as shown in SEQ ID NO 10 or having at least 80% identity thereto;
The LFR1 comprises/is as SEQ ID No. 11 or an amino acid sequence having at least 80% identity thereto;
the LFR2 comprises/is as SEQ ID No. 12 or an amino acid sequence having at least 80% identity thereto;
the LFR3 comprises/is as SEQ ID No. 13 or an amino acid sequence having at least 80% identity thereto;
the LFR4 comprises/is as set forth in SEQ ID No. 14 or an amino acid sequence having at least 80% identity thereto.
In other embodiments, each of the framework region amino acid sequences of an antibody or antigen binding fragment thereof provided herein may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the corresponding framework region (SEQ ID NO:7, 8, 9, 10, 11, 12, 13 or 14) described above.
In some alternative embodiments of the present invention, LFR2 comprises/is shown as SEQ ID NO. 25.
In some alternative embodiments of the present invention, LFR3 comprises/is shown as SEQ ID NO. 26.
In some alternative embodiments of the invention, the antibody or antigen binding fragment thereof binds cortisol with an affinity of KD <4.31 x 10 -9 M.
In some alternative embodiments of the invention, the antibody or antigen binding fragment thereof binds cortisol with an affinity of KD≤10 -9M、KD≤10-10M、KD≤10-11M、KD≤10-12M、KD≤10-13.
In some alternative embodiments of the invention, the antibody or antigen binding fragment thereof binds cortisol with an affinity of KD≤9.90X10 -13 M.
Antibody affinity (KD) assays are widely varied and can be classified into thermodynamic, kinetic and dynamic equilibrium assays based on the principle of detection. Among them, thermodynamic detection methods are commonly known as Isothermal Titration Calorimetry (ITC), kinetic detection methods are commonly known as Surface Plasmon Resonance (SPR) and biological membrane light interferometry (BLI), and dynamic equilibrium detection methods are commonly known as enzyme-linked immunosorbent assay (ELISA).
In some alternative embodiments of the invention, the determination of KD is performed by the method described in the examples below.
In a third aspect, embodiments of the present invention provide an antibody or antigen-binding fragment thereof, comprising a heavy chain variable region having an amino acid sequence shown in SEQ ID NO. 17 and/or a light chain variable region having an amino acid sequence shown in any one of SEQ ID NO. 18, 19 or 20.
In some optional embodiments of the invention, the heavy chain variable region and the light chain variable region of the first aspect or the third aspect described above are selected from any combination of:
Combination of two or more kinds of materials Heavy chain variable region Light chain variable region
1 SEQ ID NO:17 SEQ ID NO:18
2 SEQ ID NO:17 SEQ ID NO:19
3 SEQ ID NO:17 SEQ ID NO:20
。
In some alternative embodiments of the invention, the antibody or antigen-binding fragment thereof of the first, second or third aspects above further comprises a constant region.
In some alternative embodiments of the invention, the constant region comprises a heavy chain constant region and/or a light chain constant region.
In some alternative embodiments of the invention, the heavy chain constant region is selected from the group consisting of the heavy chain constant region of either IgG, igA, igM, igE or IgD or a combination of segments of multiple heavy chain constant regions.
In some alternative embodiments of the invention, the heavy chain constant region comprises a CH1 region of IgG, a hinge region of IgG, a CH2 region of IgM, a CH3 region of IgM, and/or a CH4 region of IgM.
In some alternative embodiments of the invention, the IgG is selected from IgG1, igG2, igG3, or IgG4.
In some alternative embodiments of the invention, the light chain constant region is selected from kappa-type or lambda-type light chain constant regions.
In some alternative embodiments of the invention, the constant region is of a species derived from bovine, equine, dairy cow, porcine, ovine, murine, canine, feline, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, chicken, or human.
In some alternative embodiments of the invention, the constant region is of murine species origin.
In some alternative embodiments of the invention, the heavy chain constant region sequence (CH) is shown in SEQ ID NO. 15 and the light chain constant region (CL) sequence is shown in SEQ ID NO. 16.
In other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the constant region (SEQ ID NO:15 or 16) described above.
In some alternative embodiments of the invention, the antigen binding fragment is selected from any one of F (ab ') 2, fab', fab, fv, and scFv of the antibody.
The antigen binding fragments of the above antibodies typically have the same binding specificity as the antibody from which they were derived. It will be readily appreciated by those skilled in the art from the teachings herein that antigen binding fragments of the above antibodies may be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by methods of chemical reduction cleavage of disulfide bonds. The antigen binding fragments described above are readily available to those skilled in the art based on the disclosure of the structure of the intact antibodies.
The antigen binding fragments of the above antibodies may also be synthesized by recombinant genetic techniques also known to those skilled in the art or by, for example, automated peptide synthesizers such as those sold by Applied BioSystems and the like.
In a fourth aspect, the invention provides an antibody or antigen binding fragment thereof, comprising a heavy chain and/or a light chain, wherein the heavy chain has an amino acid sequence shown in any one of SEQ ID NO. 21, and the light chain has an amino acid sequence shown in any one of SEQ ID NO. 22, 23 and 24.
In some alternative embodiments of the invention, the antibody or antigen binding fragment thereof of the first, second, third or fourth aspects above, comprises a heavy chain and a light chain in any one of the following combinations:
Combination of two or more kinds of materials Heavy chain Light chain
1 SEQ ID NO:21 SEQ ID NO:22
2 SEQ ID NO:21 SEQ ID NO:23
3 SEQ ID NO:21 SEQ ID NO:24
In a fifth aspect, the invention provides an antibody conjugate comprising an antibody or antigen binding fragment thereof as described above.
In some alternative embodiments of the invention, the above antibody conjugate further comprises biotin or a biotin derivative conjugated to the antibody or antigen binding fragment thereof.
In some alternative embodiments of the invention, the antibody conjugate further comprises a label conjugated to the antibody or antigen binding fragment thereof.
In some alternative embodiments of the invention, the above-mentioned markers refer to a class of substances having properties such as luminescence, color development, radioactivity, etc., that can be directly observed by the naked eye or detected by an instrument, by which qualitative or quantitative detection of the corresponding target can be achieved.
In some alternative embodiments of the invention, the labels include, but are not limited to, fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle-based labels.
In the actual use process, a person skilled in the art can select a suitable marker according to the detection conditions or actual needs, and no matter what marker is used, the marker belongs to the protection scope of the invention.
In some alternative embodiments of the invention, the fluorescent dyes include, but are not limited to, fluorescein-based dyes and derivatives thereof (including, but not limited to, fluorescein Isothiocyanate (FITC) hydroxy-light (FAM), tetrachlorolight (TET), and the like, or analogs thereof), rhodamine-based dyes and derivatives thereof (including, but not limited to, red Rhodamine (RBITC), tetramethyl rhodamine (TAMRA), rhodamine B (TRITC), and the like, or analogs thereof), cy-based dyes and derivatives thereof (including, but not limited to, cy2, cy3B, cy3.5, cy5, cy5.5, cy3, and the like, or analogs thereof), alexa-based dyes and derivatives thereof (including, but not limited to, alexa-Fluor 350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 700, 750, and the like, or analogs thereof), and protein-based dyes and derivatives thereof (including, but not limited to, for example, phycoerythrin (PE), phycocyanin (PC), allophycocyanin (preCP), and the like).
In some alternative embodiments of the invention, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate deoxygenase.
In some alternative embodiments of the invention, the radioisotope includes, but is not limited to 212Bi、131I、111In、90Y、186Re、211At、125I、188Re、153Sm、213Bi、32P、94mTc、99mTc、203Pb、67Ga、68Ga、43Sc、47Sc、110mIn、97Ru、62Cu、64Cu、67Cu、68Cu、86Y、88Y、121Sn、161Tb、166Ho、105Rh、177Lu、172Lu and 18F.
In some alternative embodiments of the present invention, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridine esters and its derivatives, dioxane and its derivatives, lothecine and its derivatives, and peroxyoxalate and its derivatives.
In some alternative embodiments of the invention, the nanoparticle-based labels include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.
In some alternative embodiments of the invention, the colloids include, but are not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.
In some alternative embodiments of the invention, the colloidal metals include, but are not limited to, colloidal gold, colloidal silver, and colloidal selenium.
In some alternative embodiments of the invention, the colloidal metal is colloidal gold.
In some alternative embodiments of the invention, the above antibody conjugate further comprises a solid support coupled to the antibody or antigen binding fragment thereof.
In some alternative embodiments of the invention, the solid support is selected from the group consisting of microspheres, plates, and membranes.
In some alternative embodiments of the invention, the solid support includes, but is not limited to, magnetic microspheres, plastic microparticles, microplates, glass, capillaries, nylon, and nitrocellulose membranes.
In a sixth aspect, the invention provides a reagent or kit comprising an antibody or antigen binding fragment thereof as described above or an antibody conjugate as described above.
As previously mentioned, the antibodies or antigen-binding fragments thereof of some embodiments or examples of the invention are capable of efficiently binding to cortisol, and therefore, reagents or kits comprising the cortisol antibodies or antigen-binding fragments thereof are capable of efficiently performing qualitative or quantitative detection of cortisol. The reagent or the kit provided by the invention can be used for detection of specific binding properties of cortisol and antibodies thereof, such as immunoblotting, immunoprecipitation and the like. As previously mentioned, the antibodies or antigen binding fragments thereof in some embodiments or examples of the invention have a higher binding activity or affinity to cortisol, and therefore the reagents or kits comprising the antibodies or antigen binding fragments thereof have a higher detection sensitivity or specificity.
In a seventh aspect, the present invention provides a method of detecting cortisol comprising a) contacting an antibody or antigen binding fragment, antibody conjugate, reagent or kit as described above with cortisol in a sample to be detected under conditions sufficient for an antibody/antigen binding reaction to occur to form an immune complex, and b) detecting the presence of said immune complex, the presence of said complex being indicative of the presence of said antigen in said test sample.
In an eighth aspect, the invention provides a nucleic acid molecule encoding an antibody or antigen binding fragment thereof as described above.
In a ninth aspect, the present invention provides a vector comprising the nucleic acid molecule described above.
In a tenth aspect, the present invention provides a cell comprising the vector described above.
In an eleventh aspect, the invention provides a method of producing an antibody or antigen-binding fragment thereof comprising culturing a cell as described above.
In a twelfth aspect, the invention provides the use of an antibody as described above or an antigen binding fragment thereof, an antibody conjugate or a reagent or kit as described above for the detection of cortisol or for the preparation of a product for the detection of cortisol.
On the basis of the present disclosure of the amino acid sequence of an antibody or antigen-binding fragment thereof, it is readily apparent to those skilled in the art that the preparation of the antibody or antigen-binding fragment thereof by genetic engineering techniques or other techniques (chemical synthesis, recombinant expression), e.g., isolation and purification from a culture of recombinant cells capable of recombinantly expressing an antibody or antigen-binding fragment thereof as described in any of the above, is within the scope of the present disclosure, irrespective of the technique used to prepare the antibody or antigen-binding fragment thereof.
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of formulations or unit doses herein, some methods and materials are now described. Unless otherwise indicated, techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.
Unless otherwise indicated, practice of the present invention will employ conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the ability of a person skilled in the art. Such techniques are well explained in the literature, e.g., in the molecular cloning laboratory Manual (Molecular Cloning: ALaboratory Manual), second edition (Sambrook et al, 1989), oligonucleotide Synthesis (Oligonucleotide Synthesis) (M.J.Gait et al, 1984), animal cell Culture (ANIMAL CELL Culture) (R.I. Freshney, 1987), enzymatic methods (Methods in Enzymology) (academic Press Co., ltd. (ACADEMIC PRESS, inc.), experimental immunology Manual (Handbook of Experimental Immunology) (D.M.Weir and C.Blackwell, inc.), mammalian cell gene transfer Vectors (GENE TRANSFER Vectors for MAMMALIAN CELLS) (J.M.Miller and M.P.Calos, 1987), contemporary molecular biology methods (F.M.Ausubel et al, 1987), polymerase chain reactions (28) (J.M.Weir. And C.Blackwell, inc.), PCR methods (J.34.J.37, J.J.37, J.F.37) and PCR methods (J.37, J.F.37, J.J.F.37, J.J.J.J.F.37, J.J.J.J.J.J.J.J.F.J.J.J.J.J.F.J.J.J.L).
The features and capabilities of the present invention are described in further detail below in connection with the examples.
Example 1 preparation of Anti-CORT 20D9 monoclonal antibody
Restriction enzymes, PRIME STAR DNA polymerase in this example were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO company. BD SMART TM RACE cDNA Amplification Kit kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen. Primer synthesis and gene sequencing were accomplished by Invitrogen corporation. The hybridoma cell strain secreting the Anti-CORT 20D9 monoclonal antibody is the hybridoma cell strain prepared in the laboratory and is recovered for later use.
(1) Antibody Gene production
MRNA is extracted from hybridoma cell strain secreting Anti-CORT 20D9 monoclonal antibody, DNA product is obtained through RT-PCR method, the product is inserted into pMD-18T vector after A adding reaction by rTaq DNA polymerase, and is transformed into DH5 alpha competent cells, HEAVY CHAIN and LIGHT CHAIN gene clones are respectively taken after colony growth, and each 4 clones are sent to gene sequencing company for sequencing.
(2) Sequence analysis of Anti-CORT 20D9 antibody variable region genes
The gene sequence obtained by sequencing is placed in a kabat antibody database for analysis, and VNTI 11.5.5 software is used for analysis to determine that the amplified genes of the heavy chain and light chain primer pair are correct, wherein the VL gene sequence in the LIGHT CHAIN amplified gene fragment is 321bp, the front of the VL gene sequence is 57bp leader peptide sequence, and the VH gene sequence in the HEAVY CHAIN primer pair amplified gene fragment is 357bp, belongs to the VH1 gene family, and the front of the VL gene fragment is 57bp leader peptide sequence.
(3) Construction of recombinant antibody expression plasmids
pcDNATM 3.4Vector is a constructed eukaryotic expression vector of recombinant antibody, which has been introduced with HindIII, bamHI, ecoRI and other polyclonal enzyme cutting sites and named pcDNA3.4A expression vector, 3.4A expression vector, VL and VH gene specific primers of the antibody are designed according to the result of gene sequencing of the antibody variable region in pMD-18T, and both ends have HindIII, ecoRI enzyme cutting sites and protective bases respectively, and a LIGHT CHAIN gene fragment of 0.70kb and a HEAVY CHAIN gene fragment of 1.40kb are amplified by a PCR amplification method.
The HEAVY CHAIN and LIGHT CHAIN gene fragments are respectively cut by HindIII/EcoRI double enzyme, the 3.4A vector is cut by HindIII/EcoRI double enzyme, the HEAVY CHAIN gene and LIGHT CHAIN gene after the fragments and the vector are purified and recovered are respectively connected with the 3.4A expression vector, and recombinant expression plasmids of HEAVY CHAIN and LIGHT CHAIN are respectively obtained.
2. Recombinant antibody production
Resuscitate HEK293 cells in advance, subculture to a 200ml system to enable the cell density to reach 3-5×10 6 cells/ml, the cell density to reach the concentration of selected antibodies and cell viability to be more than 95%, centrifugally clean the cells, re-dissolve the cells with a culture medium, simultaneously adjust the cell density to 2.9×10 6 cells/ml, re-dissolve the cells with the culture medium, and simultaneously serve as a cell dilution. The medium was used to prepare dilutions of plasmid DNA and transfection reagent, respectively. Adding transfection reagent diluent into plasmid DNA diluent, mixing uniformly, standing at room temperature for 15min, slowly adding the mixture into cell diluent within 1min, mixing uniformly, sampling, counting, recording and observing activity of transfected cells, culturing in a 35 ℃ constant temperature incubator at a rotating speed 120rmp and a CO2 content of 8%, and centrifuging and collecting samples after 13 days. The supernatant was affinity purified using a proteona affinity column. 6ug of the purified antibody was subjected to reducing SDS-PAGE, and the electrophoresed pattern was as shown. Two bands were shown after reducing SDS-PAGE, 1 Mr was 50KD (heavy chain) and the other Mr was 28KD (light chain).
The obtained antibody was designated as Anti-CORT 20D9Rmb1, and the Anti-CORT 20D9Rmb1 was mutated to obtain a mutated antibody, the sequences of the heavy chain (H) and the light chain (L) of which are shown in the following table:
TABLE 2 antibody sequences
Antibody name Heavy chain Light chain
Anti-CORT 20D9Rmb1 SEQ ID NO:21 SEQ ID NO:22
Anti-CORT 20D9Rmb2 SEQ ID NO:21 SEQ ID NO:23
Anti-CORT 20D9Rmb3 SEQ ID NO:21 SEQ ID NO:24
Example 2 detection of Performance of antibodies
1. Affinity analysis
Using the AMC sensor, the purified antibodies were diluted to 10ug/ml with PBST, and cortisol-BSA (obtained from the Phpeng organism) was diluted gradient with PBST.
The flow was equilibrated for 60s in buffer 1 (PBST), antibody 300s immobilized in antibody solution, incubation for 180s in buffer 2 (PBST), binding for 420s in antigen solution, dissociation for 1200s in buffer 2, sensor regeneration with 10mM pH 1.69GLY solution and buffer 3 (PBST), and data output. (KD represents equilibrium dissociation constant, i.e., affinity; kon represents binding rate; kdis represents dissociation rate. PBST major component Na2 HPO4+NaCl+TW-20).
TABLE 3 affinity data
Sample name KD Kon kdis
Control 4.31E-9 1.72E+04 7.42E-05
Anti-CORT 20D9Rmb1 3.03E-14 3.30E+06 1.00E-07
Anti-CORT 20D9Rmb2 9.30E-13 3.04E+06 2.83E-06
Anti-CORT 20D9Rmb3 9.90E-13 3.20E+06 3.17E-06
2. Activity assay
The coating solution (main component NaHCO 3) was diluted with cortisol-BSA (from Phpeng organism) to 3ug/ml, 100uL per well, 4℃overnight, the next day the wash solution (main component Na2 HPO4+Nacl) was washed 2 times, the blocking solution (20% BSA+80% PBS) was added, 120uL per well, 37℃for 1h, the plates were dried, the diluted purified and control antibodies were added, 100uL per well, 37℃for 30min, the wash solution was washed 5 times, the goat anti-mouse IgG-HRP was added, 100uL per well, 37℃for 30min, the wash solution was washed 5 times, the plates were dried, the developing solution A (50 uL per well) was added, the developing solution B (50 uL per well) was added, 10min, the stop solution was added, and the OD value was read at 450nm (reference 630 nm) on the microplate reader.
Remarks are liquid A (main component citric acid+sodium acetate+acetanilide+carbamide peroxide), liquid B (main component citric acid+EDTA.2Na+TMB+concentrated HCL), and stop solution (EDTA.2Na+concentrated H2SO 4)
TABLE 4 Activity data
Concentration (ng/ml) 123.457 41.152 13.717 4.572 1.524 0.000
Control 1.190 0.762 0.391 0.200 0.097 0.016
Anti-CORT 20D9Rmb1 1.896 0.977 0.486 0.250 0.132 0.019
Anti-CORT 20D9Rmb2 1.891 0.979 0.488 0.253 0.136 0.016
Anti-CORT 20D9Rmb3 1.888 0.984 0.479 0.257 0.139 0.023
3. Stability assessment
Placing the antibody at 4 ℃, -80 ℃ (refrigerator) and 37 ℃ (incubator) for 21 days, taking 7 days, 14 days and 21 days for state observation, and detecting the activity of the 21 days, wherein the results show that no obvious protein state change is seen in the antibody placed for 21 days under three examination conditions, and the activity is not in a descending trend along with the increase of the examination temperature, thus indicating that the antibody is stable. Table 5 below shows the results of the detection of OD by the antibody Anti-CORT 20D9Rmb on a 21-day basis.
Table 5 stability data
Sample concentration (ng/ml) 123.457 41.152 0.000
4 ℃ 21 Day sample 1.846 0.972 0.019
-80 ℃,21 Day sample 1.851 0.981 0.017
37 ℃ 21 Day sample 1.844 0.983 0.021
The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
The partial amino acid sequences involved in the present application are shown in Table 6:
TABLE 6 amino acid sequence

Claims (27)

1.一种抗皮质醇抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段具有氨基酸序列SEQ ID NO:17所示重链可变区的三个互补决定区和具有氨基酸序列SEQ IDNO:18、19、20任一轻链可变区的三个互补决定区，所述互补决定区由Kabat、Chothia、IMGT、AbM或Contact任意一种系统或多种系统组合定义。1. An anti-cortisol antibody or an antigen-binding fragment thereof, characterized in that the antibody or the antigen-binding fragment thereof has three complementarity determining regions of the heavy chain variable region shown in the amino acid sequence SEQ ID NO: 17 and three complementarity determining regions of the light chain variable region having the amino acid sequence of any one of SEQ ID NO: 18, 19, and 20, and the complementarity determining regions are defined by any one system or a combination of multiple systems of Kabat, Chothia, IMGT, AbM or Contact. 2.一种抗皮质醇抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段包括如下互补决定区：2. An anti-cortisol antibody or an antigen-binding fragment thereof, characterized in that the antibody or the antigen-binding fragment thereof comprises the following complementary determining regions: HCDR1的氨基酸序列如SEQ ID NO:1所示；The amino acid sequence of HCDR1 is shown in SEQ ID NO: 1; HCDR2的氨基酸序列如SEQ ID NO:2所示；The amino acid sequence of HCDR2 is shown in SEQ ID NO: 2; HCDR3的氨基酸序列如SEQ ID NO:3所示；The amino acid sequence of HCDR3 is shown in SEQ ID NO: 3; LCDR1的氨基酸序列如SEQ ID NO:4所示；The amino acid sequence of LCDR1 is shown in SEQ ID NO:4; LCDR2的氨基酸序列如SEQ ID NO:5所示；The amino acid sequence of LCDR2 is shown in SEQ ID NO:5; LCDR3的氨基酸序列如SEQ ID NO:6所示。The amino acid sequence of LCDR3 is shown in SEQ ID NO:6. 3.根据权利要求1或2所述的抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段还具有HFR1、HFR2、HFR3、HFR4、LFR1、LFR2、LFR3和LFR4中的至少之一。3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that the antibody or antigen-binding fragment thereof further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4. 4.根据权利要求3所述的抗体或其抗原结合片段，其特征在于，4. The antibody or antigen-binding fragment thereof according to claim 3, characterized in that: 所述HFR1包括SEQ ID NO:7或与其具有至少80％同一性的氨基酸序列；The HFR1 comprises SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto; 所述HFR2包括SEQ ID NO:8或与其具有至少80％同一性的氨基酸序列；The HFR2 comprises SEQ ID NO: 8 or an amino acid sequence having at least 80% identity thereto; 所述HFR3包括SEQ ID NO:9或与其具有至少80％同一性的氨基酸序列；The HFR3 comprises SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto; 所述HFR4包括SEQ ID NO:10或与其具有至少80％同一性的氨基酸序列；The HFR4 comprises SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto; 所述LFR1包括SEQ ID NO:11或与其具有至少80％同一性的氨基酸序列；The LFR1 comprises SEQ ID NO: 11 or an amino acid sequence having at least 80% identity thereto; 所述LFR2包括SEQ ID NO:12或与其具有至少80％同一性的氨基酸序列；The LFR2 comprises SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto; 所述LFR3包括SEQ ID NO:13或与其具有至少80％同一性的氨基酸序列；The LFR3 comprises SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto; 所述LFR4包括SEQ ID NO:14或与其具有至少80％同一性的氨基酸序列。The LFR4 comprises SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto. 5.根据权利要求1至2、4任一项所述的抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段以KD＜4.31×10-9M的亲和力结合皮质醇。5 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof binds to cortisol with an affinity of KD<4.31×10 −9 M. 6.一种抗皮质醇抗体或其抗原结合片段，包含重链可变区和轻链可变区，其特征在于，所述重链可变区氨基酸序列如SEQ ID NO:17所示；所述轻链可变区氨基酸序列如SEQ IDNO:18、19、20任一所示。6. An anti-cortisol antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, characterized in that the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO: 17; the amino acid sequence of the light chain variable region is as shown in any one of SEQ ID NO: 18, 19, and 20. 7.根据权利要求1至2、4至6任一项所述的抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段还包含恒定区。7. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2 and 4 to 6, characterized in that the antibody or antigen-binding fragment thereof further comprises a constant region. 8.根据权利要求7所述的抗体或其抗原结合片段，其特征在于，所述恒定区包括重链恒定区和轻链恒定区。8. The antibody or antigen-binding fragment thereof according to claim 7, wherein the constant region comprises a heavy chain constant region and a light chain constant region. 9.根据权利要求8所述的抗体或其抗原结合片段，其特征在于，所述重链恒定区选自IgG1、IgG2、IgG3、IgG4、IgA、IgM、IgE或IgD任意一种的重链恒定区或多种重链恒定区的区段的组合。9. The antibody or antigen-binding fragment thereof according to claim 8, characterized in that the heavy chain constant region is selected from any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD heavy chain constant regions or a combination of segments of multiple heavy chain constant regions. 10.根据权利要求8所述的抗体或其抗原结合片段，其特征在于，所述重链恒定区包括IgG的CH1区、IgG的铰链区、IgM的CH2区、IgM的CH3区和/或IgM的CH4区。10. The antibody or antigen-binding fragment thereof according to claim 8, characterized in that the heavy chain constant region comprises the CH1 region of IgG, the hinge region of IgG, the CH2 region of IgM, the CH3 region of IgM and/or the CH4 region of IgM. 11.根据权利要求7所述的抗体或其抗原结合片段，其特征在于，所述恒定区的种属来源为牛、马、猪、羊、鼠、狗、猫、兔、驴、鹿、貂、鸡、鸭、鹅或人。11. The antibody or antigen-binding fragment thereof according to claim 7, wherein the constant region is derived from cattle, horses, pigs, sheep, mice, dogs, cats, rabbits, donkeys, deer, minks, chickens, ducks, geese or humans. 12.根据权利要求7所述的抗体或其抗原结合片段，其特征在于，所述恒定区的种属来源为鼠。12. The antibody or antigen-binding fragment thereof according to claim 7, wherein the species origin of the constant region is mouse. 13.根据权利要求8所述的抗体或其抗原结合片段，其特征在于，所述重链恒定区序列如SEQ ID NO:15所示或与其具有至少80％同一性，所述轻链恒定区序列如SEQ ID NO:16所示或与其具有至少80％同一性。13. The antibody or antigen-binding fragment thereof according to claim 8, characterized in that the heavy chain constant region sequence is as shown in SEQ ID NO: 15 or has at least 80% identity thereto, and the light chain constant region sequence is as shown in SEQ ID NO: 16 or has at least 80% identity thereto. 14.根据权利要求1至2、4至6任一项所述的抗体或其抗原结合片段，其特征在于，所述抗原结合片段选自所述抗体的F(ab’)2、Fab’、Fab、Fv和scFv中的任意一种。14. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2 and 4 to 6, characterized in that the antigen-binding fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody. 15.一种抗皮质醇抗体，包括重链和轻链，其特征在于，所述重链的氨基酸序列如SEQID NO:21任一所示；所述轻链的氨基酸序列如SEQ ID NO:22、23、24任一所示。15. An anti-cortisol antibody, comprising a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NO: 21; and the amino acid sequence of the light chain is as shown in any one of SEQ ID NO: 22, 23, and 24. 16.一种抗体偶联物，其特征在于，所述抗体偶联物包括权利要求1至14任一项所述的抗体或其抗原结合片段或权利要求15所述的抗体。16 . An antibody conjugate, characterized in that the antibody conjugate comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the antibody according to claim 15 . 17.根据权利要求16所述的抗体偶联物，其特征在于，所述抗体偶联物还包括与所述抗体或其抗原结合片段偶联的生物素或生物素衍生物。17. The antibody conjugate according to claim 16, characterized in that the antibody conjugate further comprises biotin or a biotin derivative conjugated to the antibody or antigen-binding fragment thereof. 18.根据权利要求16所述的抗体偶联物，其特征在于，所述抗体偶联物还包括与所述抗体或其抗原结合片段偶联的标记物。18. The antibody conjugate according to claim 16, characterized in that the antibody conjugate further comprises a label coupled to the antibody or the antigen-binding fragment thereof. 19.根据权利要求18所述的抗体偶联物，其特征在于，所述标记物选自荧光染料、酶、放射性同位素、化学发光试剂和纳米颗粒类标记物。19. The antibody conjugate according to claim 18, characterized in that the label is selected from fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent reagents and nanoparticle labels. 20.根据权利要求16所述的抗体偶联物，其特征在于，所述抗体偶联物还包括与所述抗体或其抗原结合片段偶联的固相载体。20. The antibody conjugate according to claim 16, characterized in that the antibody conjugate further comprises a solid phase carrier coupled to the antibody or antigen-binding fragment thereof. 21.根据权利要求20所述的抗体偶联物，其特征在于，所述固相载体选自微球、板和膜。21. The antibody conjugate according to claim 20, characterized in that the solid phase carrier is selected from microspheres, plates and membranes. 22.一种试剂或试剂盒，其特征在于，所述试剂或试剂盒包括权利要求1至14任一项所述的抗体或其抗原结合片段或权利要求15所述的抗体或权利要求7所述的抗体偶联物。22. A reagent or a kit, characterized in that the reagent or the kit comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody according to claim 15, or the antibody conjugate according to claim 7. 23.权利要求1至14任一项所述的抗体或其抗原结合片段、权利要求15所述的抗体、权利要求16至21所述的抗体偶联物，或者权利要求22所述的试剂或试剂盒在制备检测皮质醇产品中的用途，其特征在于，包括：23. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody according to claim 15, the antibody conjugate according to claims 16 to 21, or the reagent or kit according to claim 22 in the preparation of a product for detecting cortisol, characterized in that it comprises: a)在足以发生抗体/抗原结合反应的条件下，使权利要求1至14任一项所述的抗体或其抗原结合片段、权利要求15所述的抗体、权利要求16至21所述的抗体偶联物，或者权利要求22所述的试剂或试剂盒与待检测样品中的皮质醇接触形成免疫复合物；和a) contacting the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody according to claim 15, the antibody conjugate according to claims 16 to 21, or the reagent or kit according to claim 22 with cortisol in a sample to be detected under conditions sufficient for an antibody/antigen binding reaction to form an immune complex; and b)检测所述免疫复合物的存在，所述复合物的存在指示测试样品中所述抗原的存在。b) detecting the presence of the immune complex, the presence of the complex indicating the presence of the antigen in the test sample. 24.一种核酸，其特征在于，其编码权利要求1至14任一项所述的抗体或其抗原结合片段或权利要求15所述的抗体。24. A nucleic acid, characterized in that it encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the antibody according to claim 15. 25.一种载体，其特征在于，其含有权利要求24所述的核酸。A vector, characterized in that it contains the nucleic acid according to claim 24. 26.一种细胞，其特征在于，其含有权利要求24所述的核酸或权利要求25所述的载体。26. A cell, characterized in that it contains the nucleic acid according to claim 24 or the vector according to claim 25. 27.一种制备权利要求1至14任一项所述的抗体或其抗原结合片段或权利要求15所述的抗体的方法，其特征在于，其包括：培养权利要求26所述的细胞。27. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the antibody according to claim 15, characterized in that it comprises: culturing the cell according to claim 26.
CN202310851433.7A 2023-07-11 2023-07-11 Anti-cortisol antibodies, reagents and kits for detecting cortisol Active CN119306830B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310851433.7A CN119306830B (en) 2023-07-11 2023-07-11 Anti-cortisol antibodies, reagents and kits for detecting cortisol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310851433.7A CN119306830B (en) 2023-07-11 2023-07-11 Anti-cortisol antibodies, reagents and kits for detecting cortisol

Publications (2)

Publication Number Publication Date
CN119306830A CN119306830A (en) 2025-01-14
CN119306830B true CN119306830B (en) 2025-06-20

Family

ID=94183698

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310851433.7A Active CN119306830B (en) 2023-07-11 2023-07-11 Anti-cortisol antibodies, reagents and kits for detecting cortisol

Country Status (1)

Country Link
CN (1) CN119306830B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120309730B (en) * 2025-06-18 2025-09-26 深圳市新产业生物医学工程股份有限公司 18-OHF antibody or antigen-binding fragment thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07159401A (en) * 1993-12-09 1995-06-23 Mieko Shimada Quantitative determination method by enzyme immunoreaction of cortisol in saliva
FR2732115B1 (en) * 1995-03-24 1997-06-13 Immunotech Sa IMMUNOLOGICAL ASSAY PROCESS FOR CORTISOL, ESPECIALLY URINARY, AND REAGENTS USED
CA2283597C (en) * 1998-10-02 2008-02-05 Ortho-Clinical Diagnostics, Inc. Reduced cortisol conjugates
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP6018917B2 (en) * 2009-12-07 2016-11-02 デシミューン セラピューティクス，インコーポレイテッド Anti-inflammatory antibodies and uses thereof
ES2629061T3 (en) * 2011-08-04 2017-08-07 Toray Industries, Inc. Method for the detection of pancreatic cancer
WO2014164067A1 (en) * 2013-03-12 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd30
SG11201604664PA (en) * 2013-12-12 2016-07-28 Stemcentrx Inc Novel anti-dpep3 antibodies and methods of use
CN104479021A (en) * 2014-10-13 2015-04-01 东南大学 A nanometer antibody aiming at cortisol and a coding sequence thereof
CN105131105A (en) * 2015-07-27 2015-12-09 苏州博源医疗科技有限公司 Cortisol immunogen, derivative, antibody, detection reagent and preparation method
JP2018203666A (en) * 2017-06-06 2018-12-27 東ソー株式会社 Antigens for isolating anti-cortisol antibodies and antibody producing methods
CN108997497B (en) * 2018-03-30 2022-02-25 华兰基因工程有限公司 Monoclonal antibody specifically binding to human plasma membrane vesicle associated protein PV-1 and preparation method and application thereof
CN112585165B8 (en) * 2018-04-25 2025-02-14 普罗米修斯生物科学公司 Optimized anti-TL1A antibody
KR20210096559A (en) * 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 Anti-IL-23p19 antibodies and uses thereof
CA3130103A1 (en) * 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
CN111635458B (en) * 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 Antibody targeting Sirpalpha or antigen binding fragment thereof, preparation and application thereof
CN111848789B (en) * 2020-07-02 2022-04-22 武汉华美生物工程有限公司 Single chain antibody against S protein of SARS-COV-2 virus and its use
CN114560939B (en) * 2022-03-30 2023-08-01 广东工业大学 A single-chain antibody for detecting cortisol and its preparation method and application
CN115925891A (en) * 2022-07-05 2023-04-07 东莞市朋志生物科技有限公司 Anti-influenza B virus antibody, reagent and kit for detecting influenza B virus
CN116041511B (en) * 2023-02-21 2025-10-10 郑州伊美诺生物技术有限公司 ACTH recombinant rabbit monoclonal antibody, preparation method and application thereof

Also Published As

Publication number Publication date
CN119306830A (en) 2025-01-14

Similar Documents

Publication Publication Date Title
CN119306829B (en) Anti-cortisol antibodies, reagents and kits for detecting cortisol
CN119306830B (en) Anti-cortisol antibodies, reagents and kits for detecting cortisol
CN119529089B (en) An antibody against growth-stimulating gene 2 protein and its application
CN119490592B (en) An anti-κ light chain antibody and its application
CN119490593B (en) An anti-κ light chain antibody and its application
CN118725123B (en) Anti-pepsinogen II antibody, reagent for detecting pepsinogen II and kit
CN119019554B (en) Anti-interleukin 6 antibody, reagent and kit for detecting interleukin 6
CN118725124B (en) Anti-pepsinogen II antibody, reagent for detecting pepsinogen II and kit
CN119285762B (en) Anti-cTnI antibodies, reagents and kits for detecting cTnI
CN119306828B (en) Anticalcitonin antibodies, reagents and kits for detecting procalcitonin
CN119019551B (en) Anti-cTnI antibodies, reagents and kits for detecting cTnI
CN119490595B (en) An Antibody Against Immunoglobulin E and Its Application
CN119569878B (en) An anti-sST2 antibody and its application
CN119306833B (en) Anti-procalcitonin antibodies, reagents and kits for detecting procalcitonin
CN119306832B (en) Anti-procalcitonin antibodies, reagents and kits for detecting procalcitonin
CN119306842B (en) Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine
CN119462922B (en) An antibody against human chorionic gonadotropin and its application
CN118725109B (en) Anti-ACTH antibodies, reagents and kits for detecting ACTH
CN119529088B (en) An antiparathyroid hormone antibody and its application
CN118772283B (en) Anti-renin antibodies, reagents and kits for detecting renin
CN119569877B (en) An anti-sST2 antibody and its application
CN118725128B (en) Anti-IgE antibody, reagent and kit for detecting IgE
CN119490594B (en) Anti-immunoglobulin E antibody and application thereof
CN119912566A (en) Anti-procalcitonin antibody and its application
CN120173120A (en) Antibody against human lambda light chain and its application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant